1357600-95-3Relevant academic research and scientific papers
Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells
Li, Hui-ying,He, Ding-Di,Zhao, Xiu-Juan,Sun, Tong-Yan,Zhang, Quan,Bai, Cui-Gai,Chen, Yue
, p. 700 - 706 (2018)
We used the concept of bioisosteres to design and synthesize a novel series of dasatinib derivatives for the treatment of leukemia. Unfortunately, most of the dasatinib derivatives did not show appreciable inhibition against leukemia cell lines K562 and H
Thiazole heterocyclic compounds, and preparation method and application thereof
-
Paragraph 0169; 0184; 0185, (2017/07/01)
The invention provides thiazole heterocyclic compounds, and a preparation method and application thereof. The thiazole heterocyclic compounds have a general structural formula as described in the specification. Results of cell-level experiments show that the thiazole heterocyclic compounds provided by the invention can inhibit proliferation of K562, HL60 and KGla cells. In particular, the compound (compound 4c) in an embodiment 3 can also inhibit proliferation of K562, HL60 and KGla cells under the condition that the concentration of the compound is lower than the concentration of a positive control drug dasatinib. Thus, the thiazole heterocyclic compounds provided by the invention can be used for treating leukemia.
An expedient approach to substituted triazolo[1,5-a][1,4]benzodiazepines via Cu-catalyzed tandem Ullmann C-N coupling/azide-alkyne cycloaddition
Majumdar,Ganai, Sintu
supporting information, p. 6192 - 6195 (2013/10/22)
An approach to the synthesis of triazolo[1,5-a][1,4]benzodiazepines comprising copper catalyzed tandem Ullmann C-N coupling followed by azide-alkyne cycloaddition has been described. The reaction of o-azidobenzylbromide and N-propargylated aniline derivat
